// App-Quantinova.ai

: BET Inhibitors Potentiate Activation of p53 and Killing of AML By MDM2 Inhibitors — a Candidate Combination Therapy

Researchers

Presenter

  • Peter D Adams

Principal Investigators

  • Anne Louise Latif

  • Ashley Newcombe

  • Neil Robertson

  • Maria Terradas

  • Helen Stewart

  • Claire Reid

  • Loveena Rishi Delori

  • Timothy Chevassut

  • Xu Huang

  • Karen Keeshan

  • Karen Blyth

  • Mhairi Copland

Medical Centers

  • Institute of Cancer Science, University of Glasgow, Glasgow, United Kingdom

  • Sanford Burnham Prebys Medical Discovery Institute, Heidelberg, CA

  • Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom

  • Haematology Department, Brighton & Sussex University Hospitals NHS Trust, Brighton, United Kingdom

  • Paul O?Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, United Kingdom

  • Paul O?Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, United Kingdom

  • The Beatson Institute for Cancer Research, Glasgow, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hematological malignancies

  • Alpha-thalassemia myelodysplasia syndrome

  • Acute myelocytic leukemia

  • Solid malignancies

Biomarkers

  • Mouse double minute 2 homolog

  • B-cell lymphoma 2

  • BCL2 Binding Component 3

  • Cyclin-dependent kinase 4

  • Tumor protein p53

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved